Gilead Sciences Reports Strong Q4 2025 Results, Sets Modest Outlook for 2026 - Alpha Spread

/

Share

Gilead Sciences announced its financial results for the fourth quarter and full year of 2025. The company reported earnings and sales that were slightly above Wall Street estimates for the quarter.

Gilead credited its strong performance to the successful U.S. launch of Yeztugo, the first twice-yearly HIV prevention therapy, as well as continuing growth in its Biktarvy and Descovy treatments.

Despite the positive quarterly results, Gilead provided a financial forecast for 2026 that was at the lower end of what analysts had expected. This cautious outlook led to a decline in Gilead’s share price during after-hours trading.

Yeztugo is Gilead's new HIV prevention therapy, given twice a year. Its launch is considered successful and contributed to the company’s growth.

Although Gilead had strong fourth quarter results, its financial forecast for 2026 was lower than analysts expected, causing investor concern.

Biktarvy and Descovy are treatments developed by Gilead, mainly used to treat or prevent HIV, and they continue to grow in sales.

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2025. “Our fourth quarter and full-year results close out a very strong year for Gilead overall, including the successful U.S. launch...

Reuters

Gilead Sciences on Tuesday reported fourth-quarter sales and profit that came in slightly above Wall Street estimates, while its 2026 financial forecast was at the lower end of analysts' expectations.

Investors Business Daily

Gilead Sciences cleanly beat fourth-quarter expectations late Tuesday, but Gilead stock could take a hit on its light guidance for 2026.

Benzinga

Gilead Sciences Inc. (NASDAQ: GILD) shares slipped in Tuesday's extended trading after the company released its fourth-quarter earnings report with weak fiscal 2026 guidance.

Benzinga

Gilead Sciences Inc. (NASDAQ: GILD) posted upbeat fourth-quarter earnings but issued weak fiscal 2026 guidance on Tuesday.

Schaeffers Research

Gilead Sciences Inc (NASDAQ:GILD) stock is up 5.7%, hitting a record high of $155.56 at last glance, after the biopharmaceutical company announced a top- and bottom-line win for the fourth quarter.

Zacks Investment Research

Gilead beats Q4 estimates on strong HIV and Liver Disease portfolio performance, but 2026 guidance tempers sentiment despite Yeztugo's solid debut.

Zacks Investment Research

Biotech leader Gilead Sciences (GILD) made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results yesterday evening.

Zacks Investment Research

ILMN tops Q4 EPS and revenue estimates, posts 42% profit jump, but shares slide 10% on margin concerns despite 2026 growth outlook.

Zacks Investment Research

LLY's Q4 beat and bold 2026 outlook highlight surging GLP-1 sales and a deep obesity pipeline.

Show All Sources

Price

143.89

Intrinsic Value

Open

Mergers & Acquisitions

Gilead Sciences has announced a definitive agreement to acquire Arcellx, a biotechnology company specializing in cancer immunotherapies, for a total value of approximately $7.8 billion. The agreement includes a cash payment of $115 per Arcellx share...

Regulatory Actions

President Donald Trump has called on 17 major pharmaceutical companies to take steps to lower drug prices for Americans within the next 60 days. This move follows an executive order he signed in May aimed at reducing U.S. drug costs by linking prices...

Mergers & Acquisitions

Gilead Sciences has announced a definitive agreement to acquire Arcellx, a biotechnology company specializing in cancer immunotherapies, for a total value of approximately $7.8 billion. The agreement includes a cash payment of $115 per Arcellx share...

Regulatory Actions

President Donald Trump has called on 17 major pharmaceutical companies to take steps to lower drug prices for Americans within the next 60 days. This move follows an executive order he signed in May aimed at reducing U.S. drug costs by linking prices...

Other News

S&P Dow Jones Indices announced that Vertiv, Lumentum, Coherent and EchoStar will be added to the S&P 500, effective before market open on March 23. The move reflects growing weight for technology and...

Oracle and OpenAI have stopped plans to expand a flagship artificial intelligence data center in Abilene, Texas after talks stalled over financing and OpenAI's changing needs, according to multiple re...

Target Corp. said it will open more than 30 new stores in 2026 as part of a push to drive long-term, sustainable growth through increased investment in its physical locations. The retailer will open...

Apple announced a new generation of laptops and processors, unveiling the M5 chip for the MacBook Air and two pro variants — M5 Pro and M5 Max — for 14‑ and 16‑inch MacBook Pro models. The M5 brings...

Apple announced the iPhone 17e, a lower-cost addition to the iPhone 17 family, positioned to help the company defend market share in a competitive handset market. The iPhone 17e is powered by Apple’s...

Novo Nordisk has announced it will reduce the list prices of its popular diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 50% in the United States. The new pricing will take effect in Janu...

Multiple plaintiffs' law firms have announced class action lawsuits against CoreWeave, Inc. (NASDAQ: CRWV) following the company's fourth-quarter 2025 results and related disclosures. The firms say th...

A senior U.S. Food and Drug Administration (FDA) official said uniQure N.V.'s experimental gene therapy for Huntington's disease did not provide sufficient evidence that it slows disease progression a...

FedEx has filed a lawsuit against the U.S. government to recover money it paid in tariffs that were implemented under former President Donald Trump. The company is seeking a full refund of these trade...

Samsara Inc. (NYSE: IOT) reported stronger-than-expected fourth-quarter and full fiscal 2026 results, driving a sizable jump in its stock after the market close. For Q4 FY26 the company reported reve...

Gap Inc. reported fiscal 2025 results showing modest top-line growth and measures to return cash to shareholders. Full-year net sales rose 2% year‑over‑year, with comparable sales up 3%—the company’s...

Costco Wholesale reported stronger-than-expected results for the second quarter of fiscal 2026, the 12-week period ended Feb. 15, 2026, and for the first 24 weeks of the fiscal year. The company post...

Shares of The Trade Desk Inc. (NASDAQ: TTD) jumped sharply on March 5, 2026, rising about 19%–21% to roughly $30.60, making the stock one of the best performers in the software sector for the day. Th...

Global defense stocks rose sharply on Monday after reports of military exchanges between the U.S., Israel and Iran, and retaliatory strikes on regional allies. The moves came amid concern the conflict...

Escalating geopolitical tensions in the Middle East have put energy exchange-traded funds (ETFs) at the center of market moves after military strikes and reported disruptions in the Strait of Hormuz....

U.S. oil prices surged this week at their fastest pace on record as rising tensions related to Iran pushed U.S. crude above $90 a barrel. The escalation in conflict has rattled global oil markets and...

Rising tensions around the Strait of Hormuz have begun to disrupt tanker traffic and raise costs across global crude markets, tightening deliverable supply and lifting price risk premiums, especially...

Private-sector employment in the United States grew by 63,000 jobs in February, according to the ADP National Employment Report produced by ADP Research with the Stanford Digital Economy Lab. ADP sai...

Broadcom shares have pulled back in 2026 after a strong 2025 rally that lifted the stock about 60%. The companys AI-focused semiconductor business has been a primary driver of revenue and profit grow...

Oracle shares received an upgrade from Oppenheimer & Co, which raised its rating to 'Outperform' and set a new price target of $185. This comes after Oracle's stock had fallen significantly since its...

Wall Street analysts have recently updated their price targets for Nvidia, showing strong confidence in the chipmaker's stock. Despite some market turbulence expected in early 2026, institutional inve...

Servier, an independent international pharmaceutical group, agreed to acquire Day One Biopharmaceuticals (Nasdaq: DAWN) for $21.50 per share in cash, valuing Day One at about $2.5 billion in equity. T...

<p>Netflix said on Thursday it has acquired InterPositive, a filmmaking technology company founded in 2022 by actor and filmmaker Ben Affleck. InterPositive develops artificial intelligence–powered to...

Astellas Pharma and Vir Biotechnology have entered into a global collaboration to develop and commercialize VIR-5500, an experimental treatment for prostate cancer. As part of the agreement, both comp...

Robinhood Ventures Fund I (RVI) priced its initial public offering at $25.00 per share for 12,615,608 common shares, creating a fund valued at $658.4 million. With the underwriter's option to purchase...

Nvidia CEO Jensen Huang said on March 4 that the company's recent $30 billion investment in OpenAI "might be the last" time it invests in the ChatGPT creator, as OpenAI is expected to pursue a public...

Once Upon a Farm, an organic children's food company co-founded by actress Jennifer Garner, has successfully gone public in the United States. The company raised nearly $198 million in its initial pub...

Back to Top

Join more than 322,700+ value investors using Alpha Spread

Create Free Account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Get AI-powered insights for any company or topic.

Open AI Assistant

Stock Screener

Discover stocks

Stock Comparison

Smarter decisions through side-by-side analysis

Intrinsic Value Calculator

Discover the true worth of your stocks

DCF Value Calculator

Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.